Amendments to the Specification

Please amend paragraph [0007] on page 2 as follows:

[0007] A new class of highly expressable and highly immunogenic VLPs has been disclosed in ~~WO 03/056905~~ WO 02/056905, which is incorporated herein by reference in its entirety. These VLPs are composed of the coat protein of RNA bacteriophages. The coat proteins are expressed recombinantly in bacteria, and the VLP does not contain the phage RNA genome and therefore cannot replicate.

Please amend paragraph [0113] on pages 37 and 38 as follows:

[0113] Thus, in one embodiment of the invention, the antigen or antigenic determinant used in conjugates, compositions or methods of the invention is a peptide derived from the VEGFR-II contact site. This provides a composition and a vaccine composition in accordance with the invention, which may have antiangiogenic properties useful for the treatment of cancer. Inhibition of tumor growth in mice using sera specific for VEGFR-2 has been demonstrated (Wei, YQ et al. (2000) Nature Medicine 6, ~~1160-1165~~ 1160-1166). Therefore, further antigenic determinants suitable for inventive compositions and antiangiogenic vaccine compositions in accordance with the invention comprise either the human VEGFR-II derived peptide with the amino acid sequence CTARTELNVGIDFNWEYPSSKHQHKK (SEQ ID NO: 99), and/or the murine VEGFR-II derived peptide having the amino acid sequence CTARTELNVGLDFTWHSPPSKSHHKK

(SEQ ID NO: 113), and/or the relevant extracellular globular domains 1-3 of the VEGFR-II.